# Comparative Efficacy and Safety if Intravesical Botulinum Toxin A Versus Platelet-Rich Plasma in the Management of Refractory Overactive Bladder : A 2 Year Study

> **NCT07693192** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Mahmoud Mohamed Farag Ali** · enrollment: 60 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **PROCEDURE:** Intravesical Botulinum Toxin A (100U)
- **PROCEDURE:** Intravesical Platelet-Rich Plasma

## Key facts

- **NCT ID:** NCT07693192
- **Lead sponsor:** Mahmoud Mohamed Farag Ali
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-30
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07693192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07693192, "Comparative Efficacy and Safety if Intravesical Botulinum Toxin A Versus Platelet-Rich Plasma in the Management of Refractory Overactive Bladder : A 2 Year Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07693192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*